ArticleMolecular and clinical oncology2014
Association of a disintegrin and metalloprotease 33 gene polymorphisms with asthma.
Article in Molecular and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.
- Association between ADAM33 polymorphisms and asthma risk: a systematic review and meta-analysis.Respiratory research · 2019Pooled it
- Genetic association of ADAM33 polymorphisms with childhood asthma in Chinese Han population: A case-control study.Medicine · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various studies reported a disintegrin and metalloprotease 33 (ADAM33) as an important susceptibility gene for asthma, which is frequently detected among certain populations. The aim of the present study was to investigate the association between single-nucleotide polymorphisms (SNPs) of the ADAM33 gene and asthma. Our case-control study included 183 patients (73 male and 110 female, mean age 42.93±13.48 years) who were admitted in the First Affiliated Hospital of Xinjiang Medical University between February, 2012 and May, 2013 and 155 healthy controls (66 male and 89 female, mean age 41.14±14.10 years). Allele-specific polymerase chain reaction technology and DNA testing training methods were applied to detect the T2 and ST+5 polymorphisms of the ADAM33 gene. The data were statistically analyzed to determine whether there exists an association between these genotypes and asthma-related morbidity. The genotypes and allele frequencies of the T2 and ST+5 SNPs of ADAM33 were not found to be significantly associated with asthma risk when compared between asthmatic patients and healthy controls (P>0.05). In addition, there was no association of the investigated SNPs with the severity of asthma. There was no significant difference in the forced vital capacity and the forced expiratory volume between patients with the ADAM33 T2 and ST+5 genotype. In conclusion, our results suggested that the T2 and ST+5 ADAM33 gene polymorphisms do not confer a significant risk of asthma or affect its severity in the population investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.